Quick Answer
Seres Therapeutics, Inc. reported Stockholders Equity of $44.22 million for the year ending 2025.
- Seres Therapeutics, Inc. showed an increase of +220.8% in Stockholders Equity from 2024 to 2025.
- This data is from Seres Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2015: $94.91 million | Q3 2015: $222.20 million | Q1 2016: $189.83 million | Q2 2016: $167.40 million | Q3 2016: $154.00 million | Q1 2017: $111.45 million | Q2 2017: $87.93 million | Q3 2017: $85.51 million | Q1 2018: $10.03 million | Q2 2018: -$13.25 million | Q3 2018: -$30.57 million | Q1 2019: -$69.83 million | Q2 2019: -$17.97 million | Q3 2019: -$32.22 million | Q1 2020: -$61.65 million | Q2 2020: -$65.58 million | Q3 2020: $188.05 million | Q1 2021: $143.71 million | Q2 2021: $101.07 million | Q3 2021: $175.74 million | Q1 2022: $80.96 million | Q2 2022: $23.06 million | Q3 2022: $67.59 million | Q1 2023: -$47.87 million | Q2 2023: $22.61 million | Q3 2023: -$15.12 million | Q1 2024: -$59.74 million | Q2 2024: -$87.07 million | Q3 2024: $23.92 million | Q1 2025: $50.47 million | Q2 2025: $32.95 million | Q3 2025: $43.70 million.
- Over the full 14 years of available data (2012 to 2025), Seres Therapeutics, Inc.'s Stockholders Equity has grown by 1,117.0%.
- Historical annual values: Fiscal year 2025: $44.22 million | Fiscal year 2024: $13.78 million | Fiscal year 2023: -$44.86 million | Fiscal year 2022: $10.78 million | Fiscal year 2021: $131.51 million | Fiscal year 2020: $174.75 million | Fiscal year 2019: -$48.32 million | Fiscal year 2018: -$48.05 million | Fiscal year 2017: $60.70 million | Fiscal year 2016: $132.63 million | Fiscal year 2015: $205.39 million | Fiscal year 2014: -$26.72 million | Fiscal year 2013: -$11.12 million | Fiscal year 2012: -$4.35 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: